Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate ...

The indication has been expanded to include use in newborns and allows patients and caregivers to apply the treatment at home ...

Kasungu South legislator and former Finance Minister, Hon. Simplex Chithyola Banda, has urged Malawians to embrace unity and reflection in the wake of the 2025 General Elections, describing the moment ...

Malawi's 2025 elections have triggered one of the biggest political shake-ups in recent memory, with more than 110 of the 193 ...

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and ...

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

Abstract Title: Phase 3, Randomized, Placebo Controlled Clinical Trial of CAN-2409+Prodrug in Combination with Standard of Care External Beam Radiation (EBRT) for Newly Diagnosed Localized Prostate ...

Despite the setback, Replimune’s CEO Sushil Patel emphasized the unmet need in advanced melanoma and the "compelling risk-benefit profile of RP1 observed in the IGNYTE trial." Patel stated that the ...

This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, ...

Las Vegas, Nevada, United States, September 12, 2025 -- Ballet, a trusted provider of non-custodial cryptocurrency cold wallets, today announced that users worldwide are now securing over one billion ...

Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIf approved, Dupixent would be the first ...